NOW ENROLLING PHASE III sunRIZE TRIAL In the study of congenital hyperinsulinism

Learn More »
sunrize logo

Quan Dong Nguyen, MD, MSc, FAAO, FARVO

Back to Careers

Dr. Nguyen is a Professor of Ophthalmology at the Byers Eye Institute, Stanford University School of Medicine. He is known for his innovative work in early proof-of-concept, first-in-human clinical trials to evaluate potential pharmacotherapeutic agents for retinal vascular and uveitic diseases. Dr. Nguyen serves as principal investigator on multiple clinical trials sponsored by the National Eye Institute and other organizations for macular edema (from diabetes and uveitis), neovascular age-related macular degeneration (AMD), and ocular inflammatory and uveitic diseases. He and his team were among the first clinician-scientists in the world to evaluate aflibercept for neovascular AMD and ranibizumab for DME. The initial results of these studies served as the foundation for subsequent trials leading to the approval of EYLEA and Lucentis by the U.S. Food and Drug Administration and other regulatory authorities. Dr. Nguyen has published over 300 peer reviewed articles and is on the Editorial Board of several journals, including the Journal of Ophthalmic Infection and Inflammation and Ophthalmic Surgery, Laser, and Imaging Retina.